| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.18 | 0.02 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.07 | 0.02 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | -0.078 | 0.02 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.076 | 0.03 |